Skip to main content

Table 1 Comparison of HBsAg-positive patients with HBsAg-negative patients

From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

  HBsAg-positive patients (No = 81)(30.9%) HBsAg-negative patients (No = 181)(69.1%) p-value
Age (years)    0.026
Range 17–75 17–86  
Median 46 51  
Sex    0.006
Male 41(50.6) 124(68.5)  
Female 40(49.4) 57(31.5)  
Stage    0.016
I/II 34(42) 105 (58)  
III/IV 47(58) 76(42)  
Liver involvement    0.027
Yes 8(9.9) 5(2.8)  
No 73(90.1) 176(97.2)  
Spleen involvement    0.024
Yes 12(14.8) 11(6.1)  
No 69(85.2) 170(93.9)  
LDH increase    0.89
> normal 40(49.4) 91(50.3)  
normal 41(50.6) 90(49.7)  
Extra node involvement    0.034
1 69(85.2) 169(93.4)  
> 1 12(14.8) 12(6.6)  
PS    0.26
1 76(93.8) 162(89.5)  
> 1 5(6.2) 19(10.5)  
IPI    0.99
0,1 46(57) 103(57)  
2,3,4 35(43) 78(43)  
Chemotherapy    0.69
Range 1–20 1–16  
Median 6 6  
Radiation    0.61
Yes 26(32.1) 64(35.4)  
No 55(67.9) 117(64.6)  
Response    0.24
CR 43(53) 103(61.7)  
PR 31(38) 48(28.7)  
SD 5(6) 8(4.8)  
PD 3(3) 8(4.8)  
NA   14  
Hepatic dysfunction before chemotherapy 17(21) 10(5.5) < 0.001
Hepatic dysfunction during chemotherapy 40(49.4) 30(16.6) < 0.001